Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 388

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands

Open access
Rose, M.R.·2013·Neuromuscular Disorders
DOI 10.1016/j.nmd.2013.08.007
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nmd.2013.08.007

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 65

  1. Benveniste, 2010, International workshop on inclusion body myositis held at the Institute of Myology, Paris, on 29 May 2009, Neuromuscul Disord, 20, 414, 10.1016/j.nmd.2010.03.014 · doi:10.1016/j.nmd.2010.03.014
  2. Hilton-Jones, 2010, Inclusion body myositis: MRC centre for neuromuscular diseases, IBM workshop, London, 13 June 2008, Neuromuscul Disord, 20, 142, 10.1016/j.nmd.2009.11.003 · DOI
  3. Griggs, 1995, Inclusion body myositis and myopathies, Annal Neurol, 38, 705, 10.1002/ana.410380504 · DOI · Paper page
  4. Chahin, 2008, Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM, Neurology, 70, 418, 10.1212/01.wnl.0000277527.69388.fe · DOI · Paper page
  5. Meyer, 2012, Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system, Nat Cell Biol, 14, 117, 10.1038/ncb2407 · DOI · Paper page
  6. Benjamin Larman H, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408–18. · DOI · Paper page
  7. Pluk, 2013, Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis, Ann Neurol, 73, 397, 10.1002/ana.23822 · DOI · Paper page
  8. Schmidt, 2008, Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle, Brain, 131, 1228, 10.1093/brain/awn053 · DOI
  9. Kitazawa, 2008, Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta, Ann Neurol, 64, 15, 10.1002/ana.21325 · DOI
  10. Muth, 2009, Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of aB-crystallin is associated with amyloid precursor protein and accumulation of bamyloid., J Neurol Neurosurg Psychiatry, 80, 1344, 10.1136/jnnp.2009.174276 · doi:10.1136/jnnp.2009.174276
  11. Keller, 2011, TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells, J Biol Chem, 286, 3970, 10.1074/jbc.M110.159392 · DOI
  12. Schmidt, 2010, Of amyloid and inflammation: causes of chronic muscle disease, e-Neuroforum, 1, 81, 10.1007/s13295-010-0010-1 · DOI
  13. Needham, 2008, Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis, J Clin Neurosci, 15, 1350, 10.1016/j.jocn.2008.01.011 · DOI
  14. Serdaroglu, 2007, Prevalence of sporadic inclusion body myositis (s-IBM) in Turkey: a muscle biopsy-based survey, Neuromuscul Disord, 17, 849, 10.1016/j.nmd.2007.06.293 · doi:10.1016/j.nmd.2007.06.293
  15. Scott, 2011, Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex, J Neuroimmunol, 235, 77, 10.1016/j.jneuroim.2011.02.011 · DOI
  16. Mastaglia, 2009, Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype, Neuromuscul Disord, 19, 763, 10.1016/j.nmd.2009.07.015 · doi:10.1016/j.nmd.2009.07.015
  17. Sivakumar, 1995, Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy, Ann Neurol, 38, 267, 10.1002/ana.410380222 · DOI
  18. Orth, 2000, Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity, Neurology, 55, 1235, 10.1212/WNL.55.8.1235 · doi:10.1212/wnl.55.8.1235
  19. Salajegheh, 2009, Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis, Muscle & Nerve, 40, 19, 10.1002/mus.21386 · DOI
  20. Gossrau, 2004, Apolipoprotein E and alpha-1-antichymotrypsin polymorphisms in sporadic inclusion body myositis, Eur Neurol, 51, 215, 10.1159/000078488 · DOI
  21. Needham, 2008, Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal, Neuromuscul Disord, 18, 150, 10.1016/j.nmd.2007.09.005 · DOI
  22. Askanas, 1996, Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy, Ann Neurol, 40, 264, 10.1002/ana.410400223 · DOI
  23. Harrington, 1995, Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis, Neurosci Lett, 183, 35, 10.1016/0304-3940(94)11108-U · DOI
  24. Love, 1996, Apolipoprotein E allele frequencies in sporadic inclusion body myositis, Muscle & Nerve, 19, 1605, 10.1002/(SICI)1097-4598(199612)19:12<1605::AID-MUS11>3.0.CO;2-Q · DOI
  25. Vasconcelos, 2002, GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM, Neurology, 59, 1776, 10.1212/01.WNL.0000039780.13681.AD · DOI
  26. Machado, 2012, Valosin containing protein (VCP) and myofibrillar myopathies (MFM) genes’ mutations are not associated with sporadic inclusion body myositis (sIBM)., JNNP, 83, 3e1
  27. Ranque-Francois, 2005, Familial inflammatory inclusion body myositis, AnnRheumDis., 64, 634
  28. Amato, 1998, Inclusion body myositis in twins, Neurology, 51, 598, 10.1212/WNL.51.2.598 · DOI
  29. Naumann, 1999, Inclusion body myositis in twins; correspondence, Neurology, 53, 656, 10.1212/WNL.53.3.656-e · DOI
  30. Sivakumar, 1997, An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families, Brain, 120, 653, 10.1093/brain/120.4.653 · DOI
  31. Griggs, 1995, Inclusion body myositis and myopathies, Ann Neurol, 38, 705, 10.1002/ana.410380504 · DOI · Paper page
  32. Lotz, 1989, Inclusion body myositis. Observations in 40 patients, Brain, 112, 727, 10.1093/brain/112.3.727 · DOI · Paper page
  33. Lindberg, 1994, Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases, Acta Neurol Scand, 89, 123, 10.1111/j.1600-0404.1994.tb01647.x · doi:10.1111/j.1600-0404.1994.tb01647.x
  34. Amato, 1996, Inclusion body myositis: clinical and pathological boundaries, Ann Neurol, 40, 581, 10.1002/ana.410400407 · DOI
  35. Badrising, 2005, Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients, J Neurol, 252, 1448, 10.1007/s00415-005-0884-y · DOI
  36. Felice, 2001, Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period, Medicine (Baltimore), 80, 320, 10.1097/00005792-200109000-00006 · DOI
  37. Cox, 2011, A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities, Brain, 134, 3167, 10.1093/brain/awr217 · DOI
  38. Rose, 2001, A prospective natural history study of inclusion body myositis: implications for clinical trials, Neurology, 57, 548, 10.1212/WNL.57.3.548 · DOI
  39. Dalakas, 2009, Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis, Brain, 132, 1536, 10.1093/brain/awp104 · doi:10.1093/brain/awp104
  40. Crosby, 1994, Hand strength: normative values, J Hand Surg Am, 19, 665, 10.1016/0363-5023(94)90280-1 · DOI · Paper page
  41. Tawil, 2002, Inclusion body myositis, Curr Opin Rheumatol, 14, 653, 10.1097/00002281-200211000-00004 · DOI
  42. Hayter, 2012, Updated assessment of the prevalence, spectrum and case definition of autoimmune disease, Autoimmun Rev, 10.1016/j.autrev.2012.02.001 · DOI · Paper page
  43. Needham, 2007, Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches, Lancet Neurol, 6, 620, 10.1016/S1474-4422(07)70171-0 · DOI · Paper page
  44. Benveniste, 2011, Long-term observational study of sporadic inclusion body myositis, Brain, 134, 3176, 10.1093/brain/awr213 · doi:10.1093/brain/awr213
  45. Peng, 2000, Disease progression in sporadic inclusion body myositis: observations in 78 patients, Neurology, 55, 296, 10.1212/WNL.55.2.296 · doi:10.1212/wnl.55.2.296
  46. Rose MR, Griggs R, Dalakas M. Immunotherapy for inclusion body myositis (Protocol for a Cochrane Review). Issue 4 ed: Update software; 1999. · doi:10.1002/14651858.cd001555
  47. Barohn, 1995, Inclusion body myositis: explanation for poor response to immunosuppressive therapy, Neurology, 45, 1302, 10.1212/WNL.45.7.1302 · DOI
  48. Dalakas, 2001, A controlled study of intravenous immunoglobulin combined with prednisolone in the treatment of IBM, Neurology, 56, 323, 10.1212/WNL.56.3.323 · DOI
  49. Muscle Study Group. Randomized pilot trial of INF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57:1566–70. · DOI
  50. Skalsky, 2008, The relationship between regional body composition and quantitative strength in facioscapulohumeral muscular dystrophy (FSHD), Neuromuscul Disord, 18, 873, 10.1016/j.nmd.2008.07.005 · DOI
  51. Skalsky, 2009, Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength, Muscle & Nerve, 39, 647, 10.1002/mus.21212 · doi:10.1002/mus.21212
  52. Vanhoutte, 2011, Modifying the Medical Research Council grading system through Rasch analyses, Brain
  53. Lowes, 2012, Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis, Muscle & Nerve, 45, 163, 10.1002/mus.22321 · doi:10.1002/mus.22321
  54. Allenbach, 2012, Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis, Neuromuscul Disord, 22, 980, 10.1016/j.nmd.2012.05.004 · doi:10.1016/j.nmd.2012.05.004
  55. Jackson, 2008, Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity, Muscle & Nerve, 37, 473, 10.1002/mus.20958 · DOI
  56. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63:718–20. · DOI
  57. Benveniste, 2011, Long-term observational study of sporadic inclusion body myositis, Brain, 134, 3176, 10.1093/brain/awr213 · doi:10.1093/brain/awr213
  58. Sadjadi, 2010, What determines quality of life in inclusion body myositis?, J Neurol Neurosurg Psychiatry, 81, 1164, 10.1136/jnnp.2009.183863 · DOI · Paper page
  59. Badrising, 2000, Epidemiology of inclusion body myositis in the Netherlands: a nationwide study, Neurology, 55, 1385, 10.1212/WNL.55.9.1385 · DOI
  60. Eccles, 1996, North of England evidence based guidelines development project: methods of guideline development, BMJ, 312, 760, 10.1136/bmj.312.7033.760 · DOI
  61. Eccles, 1996, Developing valid guidelines: methodological and procedural issues from the North of England evidence based guideline development project, Qual Health Care, 5, 44, 10.1136/qshc.5.1.44 · DOI
  62. Dalakas, 1997, Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study, Neurology., 48, 712, 10.1212/WNL.48.3.712 · DOI · Paper page
  63. Walter, 2000, High dose immunglobulin therapy in sporadic inclusion body myositis: a double blind, placebo-controlled study, J Neurol., 247, 22, 10.1007/s004150050005 · DOI
  64. Rutkove, 2002, A pilot randomized trial of oxandrolone in inclusion body myositis, Neurology., 58, 1081, 10.1212/WNL.58.7.1081 · DOI
  65. Badrising, 2002, Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo, Annal Neurol., 51, 369, 10.1002/ana.10121 · DOI

Cited by

See all 388

Metadata

Authors
Rose, M. R.
Venue
Neuromuscular Disorders
Publisher
Elsevier BV
Published
2013-12
Volume
23
Issue
12
Pages
1044-1055
ISSN
0960-8966 (ISSN-L)
DOI
10.1016/j.nmd.2013.08.007
OpenAlex
W1995588340
Cited by
388
References
1
FWCI
13.84
Type
journal article
Language
en
Open access
bronze
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Muskelsvindfonden (Denmark)
  • Association Française contre les Myopathies (France)
  • Deutsche Gesellschaft für Muskelkranke (Germany)
  • Telethon Foundation (Italy)
  • Drustvo Distrofikov Slovenije (Slovenia)
  • , Schweizerische Stiftung für die Erforschung der Muskelkrankheiten (Switzerland)
  • Prinses Beatrix Fonds (The Netherlands)
  • Vereniging Spierziekten Nederland (The Netherlands)
  • Muscular Dystrophy Campaign (UK)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.